A new real-time polymerase chain reaction (PCR) method was developed for quantitation of Enterocytozoon bieneusi DNA in sequential stool specimens from immunocompromised patients with intestinal microsporidiosis. Patients were treated with fumagillin (n = 6) or with placebo (n = 6), in a randomized comparative trial. At baseline, mean E. bieneusi DNA levels were not significantly different in stool specimens from the placebo group, compared with those from the fumagillin group (5.9 ± 0.4 vs. 5.9 ± 0.6 log10 copies/μL of stool suspension, respectively; P = .96). In the placebo group, parasitic burden remained stable during follow-up (P = .46), whereas, in the fumagillin group, E. bieneusi DNA levels dropped below the lower limit of detection in all patients (mean reduction from baseline, -4.7 log10 copies; P < .0001). Real-time PCR performed better than did semiquantitative assessments by microscopy, to measure parasitic burden. In conclusion, this real-time PCR assay is a reliable tool for quantitation of E. bieneusi DNA in stool specimens and for the monitoring of treatment efficacy.
CITATION STYLE
Menotti, J., Cassinat, B., Porcher, R., Sarfati, C., Derouin, F., & Molina, J. M. (2003). Development of a real-time polymerase-chain-reaction assay for quantitative detection of Enterocytozoon bieneusi DNA in stool specimens from immunocompromised patients with intestinal microsporidiosis. Journal of Infectious Diseases, 187(9), 1469–1474. https://doi.org/10.1086/374620
Mendeley helps you to discover research relevant for your work.